Contemporary Drug-Eluting Stents and Functional Recovery After Percutaneous Coronary Intervention: Implications for Exercise Capacity and Cardiac Rehabilitation
DOI:
https://doi.org/10.12775/QS.2026.53.69903Keywords
Percutaneous coronary intervention (PCI), drug-eluting stents (DES), cardiac rehabilitation, exercise capacity, physical activity, coronary artery disease, vascular healing, dual antiplatelet therapy (DAPT), exercise tolerance, secondary preventionAbstract
Background. Technological advances in contemporary drug-eluting stents (DES) have significantly improved the safety and effectiveness of percutaneous coronary intervention (PCI). However, most studies focus on traditional clinical endpoints, while the impact of modern PCI technologies on functional recovery and return to physical activity remains less well defined.
Aim. This review aimed to examine the relationship between contemporary PCI, vascular healing, and restoration of exercise capacity, with particular emphasis on cardiac rehabilitation.
Material and methods. A narrative review of current literature was performed, focusing on vascular healing after PCI, endothelial recovery with newer-generation DES, thrombotic and bleeding risks during exercise, and the role of exercise-based cardiac rehabilitation.
Results. Modern DES characterized by thinner struts and improved biocompatibility are associated with enhanced vascular healing and lower rates of late stent thrombosis. These features may support safer return to physical activity. However, exercise capacity depends not only on coronary patency but also on microvascular function, peripheral conditioning, and participation in rehabilitation programs. Cardiac rehabilitation plays a key role in improving fitness, quality of life, and long-term physical activity.
Conclusions. Contemporary PCI provides a stable basis for safe rehabilitation and physical activity. Optimal recovery requires integration of interventional treatment with structured exercise programs and individualized management. Future studies should include standardized functional outcomes.
References
1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: Update from the Global Burden of Disease Study 2019. J Am Coll Cardiol. 2020;76(25):2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010
2. Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: What have we learned and where are we going? J Am Coll Cardiol. 2015;66(8):963–972. https://doi.org/10.1093/eurheartj/ehv511
3. Anderson L, Oldridge N, Thompson DR, et al. Exercise-based cardiac rehabilitation for coronary heart disease. J Am Coll Cardiol. 2016;67(1):1–12. https://doi.org/10.1016/j.jacc.2015.10.044
4. Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug-eluting stents: Importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007;27(7):1500–1510.
DOI: https://doi.org/10.1161/ATVBAHA.107.144220
5. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362(18):1663–1674. https://doi.org/10.1056/NEJMoa0910496
6. Palmerini T, Benedetto U, Bacchi-Reggiani L, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials.
Lancet.2015;385(9985):2371-2382.
https://doi.org/10.1016/S0140-6736(15)60263-X
7. Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: A mixed-treatment comparison analysis of randomized trials. Circulation. 2012;125(23):2873-2891
https://doi.org/10.1161/CIRCULATIONAHA.112.097014
8. Stone GW, et al. Five-year outcomes after PCI with everolimus-eluting stents or bypass surgery for left main coronary disease. N Engl J Med. 2019;381(19):1820–1830. https://doi.org/10.1056/NEJMoa1909406
9. Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina Questionnaire: A new functional status measure for coronary artery disease. Circulation. 1995;94(7):135–141.
https://doi.org/10.1016/0735-1097(94)00397-9
10. Rumsfeld JS, Alexander KP, Goff DC, et al. Cardiovascular health status measures in clinical research. Circulation. 2013;127(22):2233–2249. https://doi.org/10.1161/CIR.0b013e3182949a2e
11. Balady GJ, Williams MA, Ades PA, et al. Core components of cardiac rehabilitation/secondary prevention programs: 2007 update. Circulation. 2007;115(20):2675–2682. https://doi.org/10.1161/CIRCULATIONAHA.106.180945
12. Piepoli MF, Hoes AW, Agewall S, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37(29):2315–2381. https://doi.org/10.1093/eurheartj/ehw106
13. Valgimigli M, Frigoli E, Heg D, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med. 2021;385(18):1643–1655. https://doi.org/10.1056/NEJMoa2108749
14. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis. Lancet. 2012;379(9824):1393–1402. https://doi.org/10.1016/S0140-6736(12)60324-9
15. Kandzari DE, Mauri L, Koolen JJ, et al. Ultrathin bioresorbable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in PCI (BIOFLOW V). Lancet. 2017;390(10105):1843–1852. https://doi.org/10.1016/S0140-6736(17)32249-3
16. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155–2166. https://doi.org/10.1056/NEJMoa1409312
17. Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month DAPT after PCI (STOPDAPT-2). JAMA. 2019;321(24):2414–2427. https://doi.org/10.1001/jama.2019.8145
18. Hahn JY, Song YB, Oh JH, et al. P2Y12 inhibitor monotherapy vs dual antiplatelet therapy after PCI (SMART-CHOICE). JAMA. 2019;321(24):2428–2437. https://doi.org/10.1001/jama.2019.8146
19. Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin followed by ticagrelor monotherapy after drug-eluting stent implantation (GLOBAL LEADERS). Lancet. 2018;392(10151):940–949. https://doi.org/10.1016/S0140-6736(18)31858-0
20. Rao SV, Kaltenbach LA, Weintraub WS, et al. Same-day discharge after elective PCI among older patients. JAMA. 2011;306(13):1461–1467. https://doi.org/10.1001/jama.2011.1409
21. Amin AP, Pinto D, House JA, et al. Same-day discharge after elective PCI: Costs and outcomes. JAMA Cardiol. 2018;2(9):1041–1049. DOI: 10.1001/jamacardio.2018.3029
22. Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in acute coronary syndromes (RIVAL). Lancet. 2011;377(9775):1409–1420. https://doi.org/10.1016/S0140-6736(11)60404-2
23. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med. 2002;346(11):793–801. https://doi.org/10.1056/NEJMoa011858
24. Hambrecht R, Walther C, Möbius-Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in stable coronary artery disease. Circulation. 2004;109(11):1371–1378. https://doi.org/10.1161/01.CIR.0000121360.31954.1F
25. Serves N, Pazart L, Damien G, et al. Adherence to cardiac rehabilitation and home exercise after myocardial infarction: a qualitative study of expectations, barriers and drivers BMC Sports Science, Medicine and Rehabilitation. 2023;15:63 https://doi.org/10.1186/s13102-023-00714-3
26. Lee S, Bohplian S, & Bronas UG. (2022).
Accelerometer use to measure physical activity in older adults with coronary artery disease: An integrative review. Journal of Cardiovascular Nursing, 38(6), 568–580.
https://pubmed.ncbi.nlm.nih.gov/37816084/
27. Kodama S, Saito K, Tanaka S, et al. Cardiorespiratory fitness and mortality. JAMA. 2009;301(19):2024–2035. https://doi.org/10.1001/jama.2009.681
28. Doll JA, Hellkamp A, Thomas L, et al. Effectiveness of cardiac rehabilitation after myocardial infarction. Am Heart J. 2015;170(5):855–864. https://doi.org/10.1016/j.ahj.2015.08.001
29. Pelliccia A, Solberg EE, Papadakis M, et al. ESC guidelines on sports cardiology. Eur Heart J. 2020;42(1):17–96. https://doi.org/10.1093/eurheartj/ehaa605
30. Tully PJ, Harrison NJ, Cheung P et al. Anxiety and Cardiovascular Disease Risk: a Review Curr Cardiol Rep 18, 120 (2016). https://doi.org/10.1007/s11886-016-0800-3
31. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans. J Am Coll Cardiol. 2006;48(1):193–202. https://doi.org/10.1016/j.jacc.2006.03.042
32. Otsuka F, Byrne RA, Yahagi K, et al. Neoatherosclerosis. Eur Heart J. 2015;35(32):2147–2159. DOI: 10.1093/eurheartj/ehv205
33. Mittleman MA, Maclure M, Tofler GH, et al. Triggering of myocardial infarction by heavy physical exertion. N Engl J Med. 1993;329(23):1677–1683. https://doi.org/10.1056/NEJM199312023292301
34. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy. Eur Heart J. 2018;39(3):213–260. https://doi.org/10.1093/eurheartj/ehx419
35. Pijls NHJ, De Bruyne B, Peels K, et al. Measurement of fractional flow reserve. N Engl J Med. 1996;334(26):1703–1708. https://doi.org/10.1056/NEJM199606273342604
36. Tonino PAL, De Bruyne B, Pijls NHJ, et al. Fractional flow reserve versus angiography for guiding PCI. N Engl J Med. 2009;360(3):213–224. https://doi.org/10.1056/NEJMoa0807611
37. De Bruyne B, Pijls NHJ, Kalesan B, et al. Fractional flow reserve–guided PCI vs medical therapy. N Engl J Med. 2012;367(11):991–1001. https://doi.org/10.1056/NEJMoa1205361
38. Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373(21):2038–2047. https://doi.org/10.1056/NEJMoa1503943
39. Afilalo J, Alexander KP, Mack MJ, et al. Frailty assessment in cardiovascular care. J Am Coll Cardiol. 2013;63(8):747–762. https://doi.org/10.1016/j.jacc.2013.09.070
40. Kedhi E, Joesoef KS, McFadden E, et al. COMPARE trial. Lancet. 2010;375(9710):201–209. https://doi.org/10.1016/S0140-6736(09)62127-9
41. Levine GN, Bates ER, Bittl JA, et al. ACC/AHA guideline update on dual antiplatelet therapy. J Am Coll Cardiol. 2016;68(10):1082–1115. https://doi.org/10.1016/j.jacc.2016.03.513
42. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention. Eur Heart J. 2021;42(34):3227–3337. https://doi.org/10.1093/eurheartj/ehab484
43. Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention guideline update. Circulation. 2011;124(22):2458–2473. https://doi.org/10.1161/CIR.0b013e318235eb4d
44. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC/EACTS myocardial revascularization guidelines. Eur Heart J. 2019;40(2):87–165. https://doi.org/10.1093/eurheartj/ehy394
45. Prince SA, Adamo KB, Hamel ME, Hardt J, Connor Gorber S, Tremblay M. Direct vs self-report physical activity measures. Int J Behav Nutr Phys Act. 2008;5:56. https://doi.org/10.1186/1479-5868-5-56
46. Troiano RP, McClain JJ, Brychta RJ, Chen KY. Evolution of accelerometer methods for physical activity research. Br J Sports Med. 2014;48(13):1019–1023. https://doi.org/10.1136/bjsports-2014-093546
47. Kereiakes DJ, Onuma Y, Serruys PW, Stone GW. Bioresorbable vascular scaffolds for coronary revascularization. Circulation. 2016;131(6):598–610. https://doi.org/10.1161/CIRCULATIONAHA.116.021539
48. Piotrowicz E, Piepoli MF, Jaarsma T, et al. Telerehabilitation in heart failure patients. Eur J Prev Cardiol. 2016;26(10):1093–1101. DOI: 10.1016/j.ijcard.2016.06.277
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Justyna Czechowicz, Paweł Czechowicz, Mikołaj Antkiewicz, Aleksandra Arczyńska-Antkiewicz, Maria Drozd, Zuzanna Kruczek, Julia Kociuba, Dorota Kołkowicz, Natalia Pawełczak, Agata Krawczyk, Martyna Kudła, Paulina Łobaza
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 60
Number of citations: 0
